| Purity | ≥99.3% |
| Molecular Weight | 4,731 Da |
| Category | Triple hormone receptor agonist (GIP / GLP-1 / glucagon) — synthetic peptide |
| Sequence | 39-amino-acid synthetic peptide on a GIP backbone with non-coded residues (Aib-2, Aib-20, alpha-Me-Leu-13) and a C20 fatty diacid conjugate for albumin binding |
Retatrutide
A synthetic triple agonist activating GIP, GLP-1, and glucagon receptors simultaneously, studied for its multi-pathway effects on weight and metabolic regulation.
Starting from $75.00
For research use only. Not for human consumption.
Storage Conditions
Lyophilized Powder (Unmixed): Store in a freezer at or below -4F (-20°C), shielded from light. Reconstituted Solution (Mixed): Store refrigerated between 36F and 46F (2-8C) and use within 28 days. Never freeze the mixed solution.
Research Overview
Retatrutide (LY3437943) was developed by Eli Lilly as an extension of incretin-based metabolic research following tirzepatide's dual GIP/GLP-1 mechanism. Coskun et al. (2018) described the design rationale for a balanced triple agonist adding glucagon receptor activity to the GIP/GLP-1 platform. A Phase 2 dose-ranging trial (Jastreboff et al., 2023, New England Journal of Medicine) randomized adults with obesity to weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, over 48 weeks, with gradual dose escalation for the higher-dose arms. The 12 mg dose produced mean weight reductions of 24.2%, with the 8 mg arm reaching 22.8% — among the largest effect sizes reported in incretin-based obesity research at the time of publication. The trial also reported substantial reductions in liver fat content among participants with elevated baseline levels. As of the most recent published data, retatrutide has progressed into Phase 3 clinical development but has not received regulatory approval. It remains an investigational compound, and its long-term safety and efficacy profile continues to be studied in ongoing trials.
Research use only. This product is intended for in vitro and laboratory research purposes only. It is not approved by the FDA for human or veterinary use. It is not a drug, food, or cosmetic, and may not be misbranded, misused, or sold for purposes other than research.
All information provided is for research and educational purposes only and does not constitute medical advice.